Telix Radiopharmaceutical Production Facility Buildout Commences
Retrieved on:
Lundi, mars 21, 2022
Company, LinkedIn, TGA, BNP Paribas, Degenerative disease, University, Day of the Walloon Region, Bank account, Prostate, Hospital, Environment, Food, TLX, 2006 Giro d'Italia, Stage 1 to Stage 11, Waste management, ASX, Australian Securities Exchange, Safety, IMBC, MTR, Cyclotron, Regulation of tobacco by the U.S. Food and Drug Administration, GLOBE, Seneffe, FDA, Gallium, Fine chemical, Pharmaceutical industry, Telix, Brussels South
MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to provide a material update on the development of its radiopharmaceutical production facility in Brussels South (Seneffe) in the Wallonia region of Belgium.
Key Points:
- MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to provide a material update on the development of its radiopharmaceutical production facility in Brussels South (Seneffe) in the Wallonia region of Belgium.
- It will also be an integral hub for Telixs R&D activities, specifically in relation to the scale-up of radioisotope production.
- Telix will also contribute 2 million from existing cash reserves for Stage 1, which is projected for completion in 1H 2023.
- Dr Christian Behrenbruch, Group CEO and Managing Director of Telix said, This manufacturing and R&D facility, and our vertically integrated operations, will further differentiate Telix as a global leader in the radiopharmaceutical industry.